Key Points

  • Judge Saylor denied the motions to dismiss, or for a more definite statement, filed by Sumit Rai, SVN Med, NVS Med, Onco Filtration, Kim de Mora and relief defendant Cancer Check Labs.
  • The court held the SEC's claims were timely under the five-year limit of 28 U.S.C. § 2462 because the complaint pleads discrete violations within the window, and noted a 10-year period applies to injunctive relief and disgorgement.
  • The court held that successive note exchanges and changes in corporate structure do not discharge earlier alleged fraud.
  • The court held the aiding-and-abetting claim against de Mora was adequately pleaded under a knowing-or-reckless standard, and that Cancer Check Labs can be pursued as a relief defendant based on its alleged receipt of technology developed with fraud proceeds.
  • The court denied the motion to transfer the case to the Northern District of Texas and the alternative request to sever the claims against de Mora.

A federal judge in Massachusetts on Nov. 20 refused to dismiss a Securities and Exchange Commission lawsuit alleging that Sumit Rai, a former venture capitalist, and two of his medical technology companies, SVN Med and NVS Med, used investor funds to pay his personal and unrelated business expenses, including the repayment of a roughly $10.6 million personal bank loan.

U.S. District Judge F. Dennis Saylor IV denied motions to dismiss filed by Rai; by SVN Med LLC, NVS Med Inc. and Onco Filtration Inc., the companies he controlled; by Kim de Mora, SVN Med's chief executive during the period at issue; and by Cancer Check Labs LLC, a company Rai formed in 2023. He also denied a request by Rai and the companies to transfer the case to the Northern District of Texas or to sever the claims against de Mora. Rai had offered nine grounds. "All of those arguments are without merit," Saylor wrote.

The ruling keeps alive the SEC's claims under Section 10(b) of the Securities Exchange Act of 1934 and Section 17(a) of the Securities Act of 1933 against Rai and the three companies, its aiding-and-abetting claim against de Mora, and its bid to recover property from Cancer Check Labs. Saylor rejected the argument that successive note exchanges into new corporate entities had wiped out the earlier claims. "A change in investment form or corporate structure does not erase fraud in hindsight," he wrote.

According to the complaint, Rai began soliciting investments in SVN Med in 2019 with materials describing its focus as cancer dialysis. In 2020, he gave investors pitch materials describing a medical device capable of filtering a patient's "entire blood volume" to remove circulating tumor cells. Investors' convertible promissory notes were later exchanged into notes of NVS Med and then Onco Filtration. In all, the SEC alleges, he raised about $26.7 million from 180 investors.

The complaint alleges that in July 2020 Rai obtained a personal line of credit from a lender identified as Bank A, pledging as collateral an SVN Med brokerage account that was substantially funded by investor money and representing that he owned 100% of the company. The SEC alleges he used the proceeds to, among other things, give a business associate $5.1 million to spend on restaurants, nightclubs and entertainment and to spend $85,000 at strip clubs. When the bank demanded repayment in April 2023, Rai allegedly paid off the $10.6 million balance with investor funds, and de Mora signed off.

The agency also alleges that Rai altered a brokerage statement sent to an institutional investor to hide the pledge, and that he told investors in September 2023 that Onco Filtration planned to sell a test for diagnosing cancer from circulating tumor cells, while intending that the company would instead supply Cancer Check Labs, two-thirds owned by Rai, with no documented obligation to pay. Cancer Check Labs has received at least $915,000 in revenue from selling Onco Filtration products but had paid it nothing as of September 2025, the complaint alleges.

Rai argued the suit, filed Jan. 15, 2026, was barred by the five-year statute of limitations in 28 U.S.C. § 2462 because the "core alleged conduct" was the 2020 loan. Saylor disagreed, pointing to allegations that Rai drew on the loan after Jan. 15, 2021, and misled investors about Onco Filtration's sales strategy in 2023. "Those are all well-pleaded discrete violations that allegedly occurred within the limitations period," he wrote. He added that the SEC's requests for an injunction and disgorgement carry a 10-year limitations period.

Saylor called Rai's argument that each note exchange discharged the prior notes "nonsensical," noting that the complaint alleges Rai "utilized shifting corporate forms specifically in order to find new ways to raise capital through fraudulent means."

On scienter, which the SEC must show for some of its claims, Rai argued that the complaint described ordinary business conduct. "It is conceivable that the evidence will show that Rai's conduct was entirely permissible commercial behavior," Saylor wrote. "But whether that is true is a question of fact." The complaint's specific allegations that Rai deliberately misled investors and misappropriated their funds were, he wrote, "easily sufficient to plead scienter."

De Mora, who is accused of aiding and abetting Rai, argued that the complaint failed to show he was aware of the specific primary violation. Saylor wrote that the statute reaches anyone who "knowingly or recklessly provides substantial assistance" to a violation and that "The First Circuit has explicitly rejected a requirement of actual knowledge." He pointed to allegations that de Mora signed the loan application knowing SVN Med assets would become collateral and told investors their money would fund clinical trials while knowing it would go to Rai's loan. "That is sufficient to state a claim for aiding and abetting," Saylor wrote.

Cancer Check Labs is named as a relief defendant. Such parties are "not accused of having violated the securities laws themselves, but who are believed to be in possession of profits from such violations," Saylor wrote, quoting a First Circuit decision. The company argued that the complaint failed to plead that it directly received investor funds. "That is beside the point," Saylor wrote, because the complaint "seeks disgorgement based on Cancer Check Labs's receipt of technology developed using the proceeds of Rai's fraud."

Rai and the companies, now located in Dallas, had to show that the relevant factors "weigh heavily" in favor of transfer. "They very clearly do not," Saylor wrote, noting that de Mora still lives in Massachusetts and that the companies were based for at least part of the period in Woburn, Massachusetts. He also refused to split off the claims against de Mora. "Without question, de Mora is properly joined in this action," he wrote.

Kathleen Burdette Shields of the U.S. Securities and Exchange Commission represented the Securities and Exchange Commission.

Saylor wrote that if Rai engaged in fraudulent conduct both before and within the limitations period, the court will have to decide at the remedies stage what civil penalty is appropriate, which he called "a question of fact appropriate for resolution later in the proceedings."